Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy

Immune checkpoint blockade (ICB) has revolutionized cancer treatment, providing remarkable clinical responses in some patients. However, the majority of patients do not respond. It is therefore crucial both to identify predictive biomarkers of response and to increase the response rates to immune ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Zemek, Rachael M., Chin, Wee Loong, Nowak, Anna K., Millward, Michael J., Lake, Richard A., Lesterhuis, W. Joost
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040078/
https://www.ncbi.nlm.nih.gov/pubmed/32133005
http://dx.doi.org/10.3389/fimmu.2020.00223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040078/
https://www.ncbi.nlm.nih.gov/pubmed/32133005
http://dx.doi.org/10.3389/fimmu.2020.00223

Ejemplares similares